Friday, March 18, 2011

OCATS AGM Meeting Regina, Sask - Ovarian Cancer Awareness & Treatment in Saskatchewan (OCATS)

Time	Saturday, March 19 · 12:00pm - 2:00pm

OCATS AGM with Judy Wright, Guest Speaker

Darlene Gray invited you · Share · Public Event



Location	Knox Met United Church, Room 105 2340 Victoria Avenue Regina

Created By	Ovarian Cancer Awareness & Treatment in Saskatchewan (OCATS), Darlene Gray

More Info	Election of Board Members Presentation of financial Statement for 2010 Vote on Change to Bylaws/ARticles/Constitution (one) Guest Speaker: Gifted Counsellor Judy Wright, Judy will share with us a new endeavor of hers, working with clients and horses to help people overcome barriers and physical and emotional pain. Light Lunch by Donation Memberships can be renewed at the door. If you are a paid member, you can vote by proxy, email darlenegray@sasktel.net

Wednesday, March 16, 2011

Alberta health board CEO lobbies doctors for patients' help

"....But more doctors are coming forward to discuss how the system hasn't let them speak freely because they face intimidation and punishment, says Independent legislative member Raj Sherman......."cont'd

Read more: http://www.edmontonjournal.com/Alberta+health+board+lobbies+doctors+patients+help/4452643/story.html#ixzz1GoiC9B2m

Main page of website: HealthNewsReview.org | Independent Expert Reviews of News Stories | Holding Health and Medical Journalism Accountable

Tuesday, March 15, 2011

Faulty Gene Helps Tumors Dodge Drugs (MCL1 and FBW7)

NIH Research Matters is on Facebook
www.facebook.com/ResearchMatters,

Doctors 2.0 conference Paris 2011 - Speakers (includes Gilles Frydman/ACOR)

Speakers include:

Gilles Frydman is the head of ACOR, the Association of Cancer Online Resources, founded in 1995 in New York, and the largest online cancer patient community with 65 000 patients and caregivers. ACOR’s 159 electronic lists deliver approximately 1.5 million email messages weekly. The ACOR community has demonstrated its ability to accelerate the distribution of quality information regarding trials, treatments, pharmacovigilance.

media: Help patients live while they are dying - "It's the right thing to do" (palliative care)

no abstract: Bilateral macular ischemia and severe visual loss following trastuzumab (Herceptin) therapy

Acta Oncologica - Summary - Magnetic resonance imaging of tumor necrosis

Acta Oncologica - summary - Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovaria

Discussion. FDG uptake (SUV_max) in the primary tumor of patients with advanced ovarian cancer was not a prognostic variable and the FDG uptake did not predict complete cytoreduction after primary surgery. Future prospective clinical trials will need to clarify if other PET tracers can serve as prognostic variables in ovarian cancer.

Monday, March 14, 2011

Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices -- American Journal of Public Health selected articles

Note: this journal is by subscription ($$$)

AJPH First Look, published online ahead of print Jan 13, 2011

April 2011, Vol 101, No. 4 | American Journal of Public Health 602-609
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2010.300027

GOVERNMENT, POLITICS, AND LAW

Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices
Sheila M. Rothman, PhD, Victoria H. Raveis, PhD, Anne Friedman, BA and David J. Rothman, PhD
Sheila M. Rothman is with the Division of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, and the Center for the Study of Society and Medicine,

College of Physicians and Surgeons, Columbia University. Victoria H. Raveis is with the Psychosocial Unit on Health, Ageing, and Community, New York University College of Dentistry, New

York. At the time of the study Anne Friedman was with the Center on Medicine as a Profession, College of Physicians and Surgeons, Columbia University. David J. Rothman is with the College
of Physicians and Surgeons, Columbia University.
Correspondence: Correspondence should be sent to Sheila M. Rothman, Center for the Study of Society and Medicine, College of Physicians and Surgeons, Columbia University,

630 West 168th St, PH 15-25, New York, NY 10032 (e-mail: smr4@columbia.edu). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" button.
Health advocacy organizations (HAOs) are influential stakeholdersin health policy. Although their advocacy tends to closely correspondwith the pharmaceutical industry's
marketing aims, the financialrelationships between HAOs and the pharmaceutical industry haverarely been analyzed.
We used Eli Lilly and Company's grant registry to examine itsgrant-giving policies. We also examined HAO Web sites to determinetheir grant-disclosure patterns.

Only 25% of HAOs that receivedLilly grants acknowledged Lilly's contributions on their Websites, and only 10% acknowledged Lilly as a grant event sponsor.

No HAO disclosed the exact amount of a Lilly grant.
As highly trusted organizations, HAOs should disclose all corporategrants, including the purpose and the amount. Absent this disclosure,legislators, regulators,

and the public cannot evaluate possibleconflicts of interest or biases in HAO advocacy.

This article has been cited by other articles:

				M. Weinberg Patient Advocacy Organizations and Corporate Relationships Am J Public Health, April 1, 2011; 101(4): 582 - 583. [Full Text] [PDF]

eLetters:

Read all eLetters

Health Advocacy Organizations: Transparency is important and so is evidence: Frances M Visco; AJPH Online, 17 Jan 2011 [Full text]
Patient Advocacy Organizations are Committed to Transparency: Myrl Weinberg; AJPH Online, 20 Jan 2011 [Full text]
Re: Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis: Jack Harris, et al.; AJPH Online, 24 Jan 2011 [Full text]

abstract: Patient Advocacy Organizations and Corporate Relationships -- Weinberg 101 (4): 582 -- American Journal of Public Health

April 2011, Vol 101, No. 4 | American Journal of Public Health 582-583
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2011.300087

LETTERS

Patient Advocacy Organizations and Corporate Relationships
Myrl Weinberg, MA
Myrl Weinberg is president of the National Health Council, Washington, DC.
Correspondence: Correspondence should be sent to Myrl Weinberg, National Health Council, 1730 M Street, NW, Suite 500, Washington, DC 20036-4561 (e-mail: mweinberg@nhcouncil.org). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" link.

Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Since its creation in 1920, the National Health Council (NHC)has been dedicated to the values of integrity, transparency,and honesty. It is crucial that the patients we represent, thepublic, and the policy makers receive accurate information abouthow patient advocacy organizations conduct their relationshipswith corporate America.
The NHC agrees with Rothman et al. about the need for transparency.¹ For this reason, any patient advocacy organization that wishesto join or retain its membership in the NHC must disclose fundingreceived from corporations and present the information in aneasily accessible manner within 6 months of the close . . . [Full Text]

eCancer video: (Avastin) Bevacizumab and Ovarian Cancer: Results of ICON7 - interview Prof. Timothy J. Perren, MD discusses sgo presentation

(NCCN) Updated Ovarian Cancer Guidelines Offer a New Treatment Choice

Note: this refers to the Japanese study published 2010 of weekly Taxol - search blog for the original study and additional commentaries

March 14, 2011 — The updated 2011 National Comprehensive Cancer Network (NCCN) Ovarian Cancer Guidelines have added a new treatment option — dose-dense paclitaxel — for the first-line treatment of stage II, III, or IV epithelial ovarian cancer.

The category 1 recommendation comes from data from the Japanese Gynecologic Oncology Group, said panel chair Robert J. Morgan, MD, professor of medicine at the City of Hope Comprehensive Cancer Center in Duarte, California, here at the NCCN 16th Annual Conference.

In a phase 3 open-label randomized controlled trial published in the Lancet (2009; 374:1331-1338), Noriyuki Katsumata and colleagues reported that dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer resulted in a significant survival advantage. The study concluded that paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.

"This was an important addition," Dr. Morgan told Medscape Medical News........"

PharmaLive: Topotarget Announces Updates on Belinostat in Two Clinical Trials - NSCLC and Ovarian Cancer (negative study ovarian/Belinostat/Carboplatin)

Ovarian cancer – GOG 0126-T (NCI-driven study)

Preliminary analysis of GOG 0126-T trial has not shown enough activity to enter into second stage. Consequently the study will be ended.

The study

The study is an open-label single-arm phase II trial with belinostat in combination with carboplatin given to patients with ovarian cancer who progress during or shortly after first-line treatment with platinum containing chemotherapy. The trial is sponsored by the GOG with support from the NCI. Belinostat is administered as a 30-minute daily IV infusion on day one through five with carboplatin being administered on day three. Treatment is given every third week and is repeated until disease progression......

(PreOvar test) Mira Dx™ Dismisses Flawed Study as “Puzzling,” and “Comparing Apples and Oranges” | Business Wire (refers to sgo presentation/KRAS mutation variant....)

Gastroenterology & Endoscopy News - Gastros Outperform Oncologists in Recognition of Inherited CRC (Lynch Syndrome/PJS/FAP....extracolonic tumors)

Note: access is free/requires registration

"......Overall, physicians benefited from the educational intervention, scoring significantly higher on exams about genetic testing for Lynch syndrome, FAP and Peutz-Jeghers syndrome post-test than at baseline. The education session also significantly improved physicians’ recognition of Lynch syndrome family pedigrees and surveillance of the disease, but did not effectively enhance awareness of extra-colonic manifestations.

Although the educational intervention improved the ability of physicians to identify families with multiple members affected by CRC, it did not help them spot extra-colonic cancers in families with Lynch syndrome. Identifying extra-colonic cancers is important because Lynch syndrome increases a person’s risk for endometrial cancer and is associated with cancers of the stomach (6%-9%); ovaries (6%-12%); and ureter and renal pelvis (3%-8%) (and others), according to the Colon Cancer Alliance for Research and Education for Lynch Syndrome...........cont'd

"Ms. (Kate) Murphy has survived ovarian and breast cancer as well as three episodes of colon cancer."

abstract: Revised Bethesda Guidelines: compliance in identifying HNPCC affected families (Lynch Syndrome)

Conclusion
Based on these results, there is a marked incompliance with revised Bethesda guidelines when assessing patients with colorectal cancer. This has a significant impact on clinical pathways for the management of HNPCC (Lynch Syndrome) families.

Sunday, March 13, 2011

ABC News - Japan Earthquake: before and after photos (google earth)

Sun Mar 13, 2011 3:00pm AEDT

Aerial photos taken over Japan have revealed the scale of devastation across dozens of suburbs and tens of thousands of homes and businesses.
Hover over each satellite photo to view the devastation caused by the earthquake and tsunami.

abstract: Pregnancy after adolescent and adult cancer: A population-based matched cohort study

"In summary, fertility-preserving attempts have succeeded in patients with ovarian or testicular cancer and in males with Hodgkin lymphoma."

abstract: Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors (endometrioid/clear cell cell types) MSH2 MSH6 MLH1

Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors.

Abstract

OBJECTIVE: Heredity is a major cause of ovarian cancer and during recent years the contribution from germline mismatch repair (MMR) gene mutations linked to Lynch syndrome has gradually been recognized.

METHODS: We characterized clinical features, tumor morphology and mismatch repair defects in all ovarian cancers identified in Swedish and Danish Lynch syndrome families.

RESULTS: In total, 63 epithelial ovarian cancers developed at mean 48 (range 30-79) years of age with 47% being early stage (FIGO stage I). Histologically, endometrioid (35%) and clear cell (17%) tumors were overrepresented. The underlying MMR gene mutations in these families affected MSH2 in 49%, MSH6 in 33% and MLH1 in 17%. Immunohistochemical loss of the corresponding MMR protein was demonstrated in 33/36 (92%) tumors analyzed.

CONCLUSION: The combined data from our cohorts demonstrate that ovarian cancer associated with Lynch syndrome typically presents at young age as early-stage, non-serous tumors, which implicates that a family history of colorectal and endometrial cancer should be specifically considered in such cases.

abstract: BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer (Slovenia)

abstract: Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer

Abstract

Recent guidance from the FDA discusses patient-reported outcomes as end points in clinical trials. Using methods consistent with this guidance, the authors developed symptom indexes for patients with advanced cancer. Input on the most important symptoms was obtained from 533 patients recruited from NCCN Member Institutions and 4 nonprofit social service organizations. Diagnoses included bladder, brain, breast, colorectal, head and neck, hepatobiliary/pancreatic, kidney, lung, ovarian, and prostate cancers and lymphoma. Physician experts in each of these diseases were also surveyed to differentiate symptoms that were predominantly disease-based from those that were predominantly treatment-induced. Results are evaluated alongside previously published indexes for 9 of these 11 advanced cancers that were created based on expert provider surveys, also implemented at NCCN Member Institutions. Final results are 11 symptom indexes that reflect the highest priorities of people affected by these 11 advanced cancers and the experienced perspective of the people who provide their medical treatment. Beyond the clinical value of such indexes, they may also contribute significantly to satisfying regulatory requirements for a standardized tool to evaluate drug efficacy with respect to symptomatology.

Saturday, March 12, 2011

Penetrance (mutations) - Wikipedia, the free encyclopedia

Associated terminology

complete penetrance. The allele is said to have complete penetrance if all individuals who have the disease-causing mutation have clinical symptoms of the disease.
highly penetrant. If an allele is highly penetrant, then the trait it produces will almost always be apparent in an individual carrying the allele.
incomplete penetrance or reduced penetrance. Penetrance is said to be reduced or incomplete when some individuals fail to express the trait, even though they carry the allele.
low penetrance. An allele with low penetrance will only sometimes produce the symptom or trait with which it has been associated at a detectable level. In cases of low penetrance, it is difficult to distinguish environmental from genetic factors.

Thursday, March 10, 2011

Bevacizumab Doubles Risk of GI Adverse Events in Key Ovarian Cancer Trial : Internal Medicine News SGO/Dr Burger/O'Malley

Visual (slides): Ovarian Cancer Pictures: Cysts, Symptoms, Tests, Stages, Treatments and Risks

News - Penn State Biochemistry and Molecular Biology Colorectal Cancer month/Lynch Syndrome excerpt

"Lynch syndrome, previously referred to as hereditary non-polyposis colorectal cancer or HNPCC, represents the most common hereditary cause of colorectal cancer.
Approximately 1 in 400 to 1 in 500 individuals in the general population are estimated to have Lynch syndrome.

Knowledge, as they say, in this condition, is power. Not only should individuals with Lynch syndrome start their colonoscopies earlier (at 20-25 years of age) and have them more frequently (every 1-2 years), they should also be screened for stomach and small intestine cancer, urinary tract cancers involving the kidneys and ureters, and the hepatobiliary tract, including the gallbladder, bile duct, pancreas and liver.

Further, women with Lynch syndrome should be aware of the increased risk for both endometrial and ovarian cancer and offered the option of prophylactic surgery following childbearing."

March 2011: Hereditary Cancer in Clinical Practice | Full text | Lynch Syndrome - is breast cancer a feature?

Background

The debate on whether or not breast cancer is in the tumor spectrum for Lynch syndrome produces a conundrum for healthcare providers.

The classic tumor spectrum for Lynch Syndrome (LS) includes colon, endometrial, ovarian, stomach, small intestine, hepatobiliary, urinary tract and brain/central nervous system cancers. Muir-Torre Syndrome (MTS) is a variant of LS that is associated with additional skin lesions including sebaceous gland tumors and keratoacanthomas. MTS was observed in 28% of LS families when assessing for MTS skin lesions [1]. It has also been reported that 10-14% of individuals with MTS present initially with breast cancer [2,3]. An extensive study published in 2002 excluded breast cancer as part of the tumor spectrum associated with LS [4].

However, more recently it was reported that DNA mismatch repair (MMR) gene deficiencies were identified in 51% of breast cancers arising in MMR mutation carriers [5]. Another study reported a male with an MLH1 mutation who had both colon and breast cancer. The breast cancer exhibited somatic reduction to homozygosity for the MLH1 mutation [6].

Here we report two unrelated families in which the proband has a germline MMR gene mutation and bilateral breast cancer, and one family in which the proband had ovarian and renal cancer and her daughter, maternal aunt and cousin had breast cancer at age 47, 59, and 48 respectively.

This raises the question are these breast cancers associated with the MMR mutations or a breast cancer susceptibility gene and what testing should be offered?

Conclusion

Our findings indicate that breast cancer is part of the spectrum of tumors in LS families in which the breast cancer segregates with the other LS associated tumors.

Additional hereditary breast cancer gene testing may not be warranted in these circumstances. A future research goal is to perform IHC on the breast tumors from these families to determine if they show loss of expression of the MMR gene that is known to be altered.

....cont'd (full free access)

Doctor and Patient - When Doctors Make Mistakes - NYTimes.com

Note: forwarded from patient safety community, sad situation/s really

Number of U.S. Cancer Survivors Grows to Nearly 12 Million

Thursday, March 10, 2011 2:31 PM

From:

"Centers for Disease Control & Prevention"

The number of cancer survivors in the United States increased from 3 million in 1971 to 11.7 million in 2007, according to a new study by CDC and the National Cancer Institute.
A cancer survivor is defined as anyone who has been diagnosed with cancer, from the time of diagnosis through the balance of his or her life. Cancer survivors largely consist of people who are 65 years of age or older and women. Many people with cancer live a long time after diagnosis; more than a million people were alive in 2007 after being diagnosed with cancer 25 years or more earlier.
Of the 11.7 million people living with cancer in 2007—

7 million were 65 years of age or older.
6.3 million were women.
4.7 million were diagnosed 10 years earlier or more.

The largest groups of cancer survivors were—

Breast cancer survivors (22%).
Prostate cancer survivors (19%).
Colorectal cancer survivors (10%).

Source: Centers for Disease Control and Prevention (CDC). Cancer survivors—United States, 2007. MMWR 2011;60(9):269–272.

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6009a1.htm

TABLE. Estimated number of living persons ever diagnosed with cancer, by age group and cancer type --- United States, January 1, 2007
Cancer type	Age group (yrs)					Overall
Cancer type	0--19	20--39	40--64	65--84	≥85	No.	(%)






Ovary	1,033	10,357	79,225	73,230	13,315	177,162	(1.5)

DMBN Exclusive: Is your MRI suite safe for patients & staff?

SGO: Menopause Symptoms Common After Gyn Cancer - in Meeting Coverage, SGO from MedPage Today

Wednesday, March 09, 2011

Linus Pauling Institute at Oregon State University (research institute vitamins/micronutriends/phytochemicals)

Researchers at the Linus Pauling Institute investigate the role that vitamins and essential minerals (micronutrients) and chemicals from plants (phytochemicals) play in human aging, immune function, and chronic diseases, especially heart disease, cancer, and neurodegenerative diseases. A major emphasis is to understand the role of oxidative stress and inflammation in disease etiology, and the preventive effects of dietary constituents with antioxidant or anti-inflammatory properties.

The goal of these studies is to understand the mechanisms by which diet, micronutrients, and dietary supplements affect disease initiation and progression and can be used in the prevention or treatment of human diseases, thereby enhancing lifespan and healthspan......cont'd

NIH/NCCAM
Center of Excellence

The Linus Pauling Institute is one of the nation's first two Centers of Excellence for Research on Complementary and Alternative Medicine designated by the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH).

ELC : Imedex e-learning center March 8th, 2011 video (30 min) interviews from SGO

Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....

Featured Activity:

Best of the Day: 2011 Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer

Dr Bradley Monk interviews 6 nationally recognized experts in GYN oncology about their interpretations of clinically relevant data presented at the annual meeting. Drs Deborah Armstrong, Barbara Goff, Tom Herzog, Warner Huh, Robert Coleman, and Robert Burger comprise the esteemed faculty.

update on ovariancancerandus blog stats - just for fun

Pageviews today: 323

Pageviews yesterday: 323

Pageviews last month: 8,231

by Country in order of most popular (top 10)

U.S.

Canada

Italy

Germany

Hungary

Vietnam

Russia

United Arab Emirates

China

Conflicts-of-interest in drug studies sneaking back into medical journals, say investigators Jewish General/McGill - press release

Subscribe to: Posts ( Atom )

Note: this journal is subscription based ($$$); most (free) abstracts are of limited value -------------------------------------------------------------------------- Surgical Clinics of North America
Volume 91, Issue 2, Pages 277-466 (April 2011)

Update on Surgical Palliative Care
Edited by Geoffrey P. Dunn



	page xi Full-Text PDF (21 KB)
	Foreword: Update on Surgical Palliative Care Ronald F. Martin pages xiii-xv Full Text \| Full-Text PDF (56 KB)
	Preface: Update on Surgical Palliative Care Geoffrey P. Dunn pages xvii-xviii Full Text \| Full-Text PDF (54 KB)
	Dedication Geoffrey P. Dunn page xix Full Text \| Full-Text PDF (23 KB)
	Surgical Palliative Care: Recent Trends and Developments Geoffrey P. Dunn pages 277-292 Abstract \| Full Text \| Full-Text PDF (119 KB)
	Are Surgeons Capable of Introspection? David W. Page pages 293-304 Abstract \| Full Text \| Full-Text PDF (92 KB)
	Spiritual Dimensions of Surgical Palliative Care Margaret J. Tarpley, John L. Tarpley pages 305-315 Abstract \| Full Text \| Full-Text PDF (95 KB)
	Inpatient Palliative Care Consultation: Enhancing Quality of Care for Surgical Patients by Collaboration Michael D. Adolph pages 317-324 Abstract \| Full Text \| Full-Text PDF (75 KB)
	Palliative Medicine in the Surgical Intensive Care Unit and Trauma Christine C. Toevs pages 325-331 Abstract \| Full Text \| Full-Text PDF (61 KB)
	Care of the Family in the Surgical Intensive Care Unit Leslie Steele Tyrie, Anne Charlotte Mosenthal pages 333-342 Abstract \| Full Text \| Full-Text PDF (82 KB)
	Palliative Surgical Oncology Nader N. Hanna, Emily Bellavance, Timothy Keay pages 343-353 Abstract \| Full Text \| Full-Text PDF (89 KB)
	Communication Skills in Palliative Surgery: Skill and Effort Are Key Thomas J. Miner pages 355-366 Abstract \| Full Text \| Full-Text PDF (362 KB)
	Image-Guided Palliative Care Procedures Jay Requarth pages 367-402 Abstract \| Full Text \| Full-Text PDF (1581 KB)
	Palliative Care in Lung Cancer Betty Ferrell, Marianna Koczywas, Fred Grannis, Annie Harrington pages 403-417 Abstract \| Full Text \| Full-Text PDF (428 KB)
	Palliative Care and Pediatric Surgery Julia Shelton, Gretchen Purcell Jackson pages 419-428 Abstract \| Full Text \| Full-Text PDF (170 KB)
	Palliative Care in Urology Jennifer N. Wu, Frederick J. Meyers, Christopher P. Evans pages 429-444 Abstract \| Full Text \| Full-Text PDF (561 KB)
	Surgical Palliative Care in Haiti Joan L. Huffman pages 445-457 Abstract \| Full Text \| Full-Text PDF (103 KB)
	Index pages 459-465 Full-Text PDF (45 KB)


	You must be a registered Imedex.com member to access this. Please enter your email address and password. Email Password Remember me Don't have an account? Forgot your password?

Blog Archives: Nov 2004 - present

#ovariancancers

Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, March 18, 2011

OCATS AGM with Judy Wright, Guest Speaker

Thursday, March 17, 2011

WHO warns against self-medicating against radiation

Objective

Conclusion

Research Highlights

Abstract

Objective

Conclusions

Research Highlights

Research Highlights

Research Highlights

Research Highlights

Wednesday, March 16, 2011

Tuesday, March 15, 2011

Monday, March 14, 2011

GOVERNMENT, POLITICS, AND LAW

eLetters:

LETTERS

Sunday, March 13, 2011

Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors.

Abstract

Abstract

Saturday, March 12, 2011

Associated terminology

Thursday, March 10, 2011

Conclusion

Number of U.S. Cancer Survivors Grows to Nearly 12 Million

Wednesday, March 09, 2011

NIH/NCCAM Center of Excellence

Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....

Featured Activity:

You must be a registered Imedex.com member to access this.

Google Scholar search "ovarian cancer"

ovarian cancer

Total Pageviews

Social Networks

pubmed: (((ovarian cancer) a...

recent comments

Ovarian Cancer Awareness (teal)

send private message to blog admin

Sandi Pniauskas Ovarian Cancer and Us

Read This:

SURVIVORS' DEBATE: The Past Decade in Ovarian Cancer

ovarian cancer

Ovarian Cancer

NIH/NCCAM
Center of Excellence